Microdosing refers to taking less than the prescribed dose of GLP-1 medications like Ozempic, Mounjaro, or Wegovy to aid in weight loss. This off-label use caters primarily to those not classified as obese or diabetic. The demand for microdosing has surged, particularly in the UK, with the Healand clinic offering treatments tailored for those over target weight. The trend originated in the US, propelled by the high cost of medications. Dr. Omar Babar explains that microdosing is especially beneficial for perimenopausal women, addressing challenges such as weight gain and fatigue.
The experimental approach involves taking less than the recommended dose of a GLP-1 medication such as Ozempic, Mounjaro, or Wegovy in the hope of curbing hunger pangs just enough to sustain weight loss.
Nevertheless, the practice is becoming increasingly popular with people who want to shift a few pounds but fall outside the drugs' target market of patients who are obese, overweight or diabetic.
Microdosing first became popular in the US, where the costs of the drugs are much higher, with Novo Nordisk's Wegovy priced at $1,349 a month and Eli Lilly's Mounjaro at $1,080.
Dr. Omar Babar states that microdosing benefits perimenopausal women who, due to hormonal changes, gain weight and struggle with fatigue and brain fog.
Collection
[
|
...
]